MVP feels the luck of the Irish

Wilson Asset Management

Wilson Asset Management

Medical Developments International (ASX: MVP) announced this week it received final approval from the Health Products Regulatory Authority of the Republic of Ireland to market and sell its inhaled pain-relief product Penthrox. The company said the approval gives MVP’s partner in Ireland and the United Kingdom, Galen, the opportunity to sell Penthrox effective immediately. Shares in MVP jumped following the announcement, and closed up 14.6% for the week. We own MVP in the investment portfolio.


1 topic

Wilson Asset Management

Wilson Asset Management has a track record of making a difference for shareholders and the community for more than 20 years. As the investment manager for eight leading LICs – WAM Capital (ASX: WAM), WAM Leaders (ASX: WLE), WAM Global (ASX: WGB),...

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.